MD Pediatrix Medical Group, Inc.
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.…
Industry Peers
Medical Care FacilitiesKey Statistics
About Pediatrix Medical Group (NYSE: MD)
›
Pediatrix Medical Group (NYSE: MD) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 4,280 employees.
The shares were at 29.94 USD on 19 November 2026, up 29.3% over 52 weeks. Its 52-week range is 17.23 USD to 33.74 USD: the price is 11.3% below the high and 73.8% above the low.
At a market capitalisation of 2.34B USD, it trades at 16.4 times trailing earnings and 11.9 times forward earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 23.7, a discount of 31% for MD.
Pediatrix Medical Group reports return on equity of 19.1%, an operating margin of 12.1% and revenue up 1.7% year over year.
Its debt exceeds its cash by 186.16M USD, a debt-to-equity ratio of 0.73. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 6 analysts cover the stock, with an average rating of Hold; their mean price target of 30.08 USD is 0.5% above the current price. The next earnings report is expected on 18 February 2027.